source
- Boehringer Ingelheim partners with Sino Biopharma on $7 billion cancer drug dealBoehringer Ingelheim announced a partnership with China's Sino Biopharmaceutical to co-develop cancer therapies. The agreement targets antibody-drug conjugates and T-cell engager platforms, with a…
- Boehringer Ingelheim strikes $7.4 billion deal with Sino Biopharma for preclinical ADC and TCE programsBoehringer Ingelheim announced a major licensing agreement with China's Sino Biopharmaceutical, paying $358 million upfront for a six‑program option covering preclinical antibody‑drug conjugates an…